文献速递妇科

一项NRG肿瘤学/GOG研究:子宫内膜样子宫内膜癌风险预测的分子分型

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2017-11-11

该研究评估了一种结合Lynch综合征筛查和分子风险分层的简化临床可及分类系统对子宫内膜样子宫内膜癌的预后意义。对NRG/GOG GOG210的肿瘤进行错配修复缺陷、POLE突变和杂合性缺失检测,982例肿瘤成功分型。拷贝数改变(CNA)组癌症特异性死亡率19%,无进展生存(HR 2.31,95%CI 1.53-3.49)和癌症特异性生存(HR 3.95,95%CI 2.10-7.44)更差。

要点

  • 982例子宫内膜样癌成功分为四类:49%拷贝数稳定、39%错配修复缺陷、8%拷贝数改变、4%POLE突变。
  • 拷贝数改变组癌症特异性死亡率19%,多因素分析癌症特异性生存HR 2.11(95%CI 1.04-4.26)。
  • POLE突变组结局改善但差异无统计学意义。

核心结论

  • 一种可轻松结合Lynch综合征筛查的简单分子分型为子宫内膜样子宫内膜癌提供了重要预后信息。
  • 这些发现支持前瞻性临床验证以及对该简化分子分型系统预测价值的进一步研究。

研究设计与样本

  • 对NRG/GOG GOG210的肿瘤评估错配修复缺陷(MSI、MMR IHC和MLH1甲基化)、POLE突变和杂合性缺失,并在部分病例中评估TP53。
  • 肿瘤被分配至四个分子类别,使用列联表和Cox比例风险方法评估分子类别与临床病理变量的关系。

主要发现

  • 982例肿瘤分子分型成功:49%为拷贝数稳定(CNS),39%为错配修复缺陷,8%为拷贝数改变(CNA),4%为POLE突变。
  • 癌症特异性死亡率:CNS肿瘤患者5%,POLE肿瘤患者2.6%,错配修复缺陷肿瘤患者7.6%,CNA肿瘤患者19%。
  • CNA组无进展生存更差(HR 2.31,95%CI 1.53-3.49),癌症特异性生存更差(HR 3.95,95%CI 2.10-7.44)。
  • POLE组结局改善,但差异无统计学意义。
  • 多因素分析中CNA类别对癌症特异性生存仍有意义(HR 2.11,95%CI 1.04-4.26)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The purpose of this study was to assess the prognostic significance of a simplified, clinically accessible classification system for endometrioid endometrial cancers combining Lynch syndrome screening and molecular risk stratification. METHODS: Tumors from NRG/GOG GOG210 were evaluated for mismatch repair defects (MSI, MMR IHC, and MLH1 methylation), POLE mutations, and loss of heterozygosity. TP53 was evaluated in a subset of cases. Tumors were assigned to four molecular classes. Relationships between molecular classes and clinicopathologic variables were assessed using contingency tests and Cox proportional methods. RESULTS: Molecular classification was successful for 982 tumors. Based on the NCI consensus MSI panel assessing MSI and loss of heterozygosity combined with POLE testing, 49% of tumors were classified copy number stable (CNS), 39% MMR deficient, 8% copy number altered (CNA) and 4% POLE mutant. Cancer-specific mortality occurred in 5% of patients with CNS tumors; 2.6% with POLE tumors; 7.6% with MMR deficient tumors and 19% with CNA tumors. The CNA group had worse progression-free (HR 2.31, 95%CI 1.53-3.49) and cancer-specific survival (HR 3.95; 95%CI 2.10-7.44). The POLE group had improved outcomes, but the differences were not statistically significant. CNA class remained significant for cancer-specific survival (HR 2.11; 95%CI 1.04-4.26) in multivariable analysis. The CNA molecular class was associated with TP53 mutation and expression status. CONCLUSIONS: A simple molecular classification for endometrioid endometrial cancers that can be easily combined with Lynch syndrome screening provides important prognostic information. These findings support prospective clinical validation and further studies on the predictive value of a simplified molecular classification system.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cosgrove CM, Tritchler DL, Cohn DE, et al. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol. 2017. PMID: 29132872. doi:10.1016/j.ygyno.2017.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。